Single Cell Technology, Inc. (SCT) and Open Monoclonal Technology, Inc. (OMT) have announced a new collaboration where OMT will use its OmniRat™ transgenic animal platform to generate human antibodies against a therapeutic target identified by SCT.
SCT will utilize its patented platform to massively screen plasma cells, measure the kinetics of secreted antibodies, and sequence the cognate light and heavy chain mRNA powered by Next Generation Sequencing (NGS).
SCT will advance and partner the program and share the economics with OMT depending on the stage of development. SCT will also have an option to develop and commercialize selected products resulting from the research.
Dr. Chun-Nan Chen, Founder and CEO of SCT said: “This partnership with OMT will demonstrate the value of delineating the antibody repertoire of the humoral response by NGS early during antibody discovery. The human immune gene sequences engineered into OmniRat by OMT will work perfectly with SCT’s massive screening and sequencing platform. We anticipate exciting results.”
Dr. Roland Buelow, Founder and CEO of OMT, continued: "We are pleased to collaborate with SCT to capture the synergies of our complementary antibody discovery technologies. This collaboration continues OMT’s process of participating in as many opportunities for development of human therapeutic antibodies as possible and establishing OmniRat as a leading transgenic animal brand.”